SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...

Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...

After a successful limited rollout of its newest insulin pump in the U.S., Tandem Diabetes Care is picking up the pace. The Mobi pump will now begin a widespread national launch, with Tandem already ...

FDA recently identified Tandem Diabetes Care’s recall of its version 2.7 of the Apple iOS t:connect mobile app used in conjunction with the t:slim X2 insulin pump with Control -IQ technology as Class ...

Tandem Diabetes Care's t:slim X2 Insulin Pump Automated Insulin Delivery System is now the first to incorporate the Abbott FreeStyle Libre 2 Plus Sensor for users in the United States. The FreeStyle ...

The US Food and Drug Administration (FDA) has announced that Tandem Diabetes Care, Inc has issued a recall regarding version 2.7 of the Apple iOS t:connect mobile app that is used in conjunction with ...

“The commercial availability of this new offering is a testament to our decade-long partnership with Dexcom and shared commitment to continued leadership in advancing AID systems,” said Mark Novara, ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID ...